Scientific Updates on Antiplatelet Therapies for the Management of Patients with Acute Coronary Syndrome

Program Dates: January 23, 2020 - January 22, 2021
Credits: 1.5 AMA PRA Category 1 Credits™; 1.5 CNE Contact Hours; 1.50 CPE Contact Hours

Scientific Updates on Antiplatelet Therapies for the Management of Patients with Acute Coronary Syndrome

Program Overview

This continuing education activity is derived from content presented at the 2019 ASHP Midyear Clinical Meeting & Exhibition in Las Vegas, Nevada. The program will highlight recent advances in antiplatelet therapeutics for acute coronary syndrome. The expert faculty will analyze current guidelines and provide insight into best approaches for developing effective patient-specific treatment plans that include the clinical pharmacy team. Navigating combination therapies while optimizing duration of antiplatelet therapies in the ACS patient will be reviewed in an interactive panel format. The faculty will also discuss the role of the pharmacist in the cardiac catheterization laboratory, covering procedural best practices, medication reconciliation, and patient education. This activity will provide learners with a better understanding of acute coronary syndrome and the central role of platelet inhibition during early management, particularly in the catheterization lab, to improve treatment and management in their pharmacy practice.

Target Audience

Pharmacists, cardiologists, primary care physicians, PAs, NPs, nurses, and other healthcare professionals involved in the management of patients with ACS

Learning Objectives

  1. Review current guidelines for antiplatelet therapies for ACS to develop the most effective patient-specific treatment plans
  2. Analyze the latest clinical trial data of antiplatelet agents for the treatment of patients with ACS
  3. Identify an optimal pharmacist role in the cardiac catheterization laboratory


John Fanikos, RPh, MBA (Course Chair)
Brigham and Women’s Hospital
Boston, Massachusetts



Snehal H. Bhatt, PharmD
Professor of Pharmacy Practice
MCPHS University
Clinical Pharmacist
Beth Israel Deaconess Medical Center
Boston, Massachusetts


Charles V. Pollack, Jr., MA, MD
Founding Board Member
Hospital Quality Foundation
Shrewsbury, New Jersey


Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:

Faculty Relationship Identified With:
Snehal H. Bhatt, PharmD Consultant/Advisor: Janssen Pharmaceuticals, Inc.; Portola Pharmaceuticals, Inc.

Speaker’s Bureau: Janssen Pharmaceuticals, Inc.; Portola Pharmaceuticals, Inc.

John Fanikos, RPh, MBA Nothing to disclose.
Charles V. Pollack Jr., MD, MA Consultant/Advisor: AstraZeneca Pharmaceuticals

Research/Grant Support: AstraZeneca Pharmaceuticals

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole Brestowski and Chelsey Benedek hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Screen Shot 2018-12-11 at 12.19.42 PM

Credit Designation Statements

AcademicCME designates this live material for a maximum of 1.50 AMA PRA Category 1 CreditsTM.

AcademicCME designates this live material for a maximum of 1.50 CNE Contact Hours, including 1.50 pharmacotherapeutic contact hours (Provider number P0491).

AcademicCME designates this continuing education activity for 1.50 CPE Contact Hours (0.15 CEUs) of continuing pharmacy education credit (JA4008190-0000-20-004-H04-P).

Financial Support

This activity has been supported by an independent educational grant from Chiesi USA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Chiesi USA, Inc. do not recommend the use of any agent outside of the labeled indications.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

1.Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

CE Inquiries/Special Needs

For all CE inquiries or special needs, please contact [email protected].


Provided by: AcademicCME-web